logo
Plus   Neg
Share
Email

Bayer: FDA Oks Natazia As First Combined Oral Contraceptive To Treat HMB

Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK) said the U.S. Food and Drug Administration, or FDA, has approved a new indication for Natazia (estradiol valerate and dienogest) tablets for the treatment of heavy menstrual bleeding, or HMB, that is not caused by any diagnosed conditions of the uterus (womb), in women who choose to use a combined oral contraceptive for contraception.

The company noted that with the above approval, Natazia is the first and only combined oral contraceptive indicated for the treatment of heavy menstrual bleeding in the U.S.

Dr. Flemming Ornskov, Head of Strategic Marketing General Medicine at Bayer HealthCare Pharmaceuticals, said, "As the first combined oral contraceptive treatment for heavy menstrual bleeding, Natazia represents a non-invasive treatment approach for this medical condition in addition to our intrauterine system Mirena. Both products underline Bayer's ongoing commitment to advancing women's health by providing them with multiple treatment options."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Facebook has removed four separate networks of accounts, pages and groups for engaging in co-ordinated inauthentic behavior on Facebook and Instagram. These networks originated from Iran and Russia and primarily targeted the US, North Africa and Latin America. These networks often posted on both sides of political issues including topics like US elections, environmental issues, racial tensions. While reporting financial results for the third quarter on Tuesday, Lockheed Martin Corp. (LMT) raised its earnings and net sales guidance for the full-year 2019, and initiated net sales outlook for the full-year 2020. For fiscal 2019, the company now expects earnings of about $21.55 per share, up... Consumer goods giant Procter & Gamble on Tuesday reported a 12 percent increase in profit for the first quarter of fiscal 2020 from last year, driven by an increase in net sales and operating margin. Both revenue and core earnings per share for the quarter beat analysts' estimates. Looking ahead, the company raised its earnings and revenue growth guidance for the full-year 2020.
Follow RTT
>